|
Amneal Pharmaceuticals Inc (AMRX) |
|
|
|
AMRX's Revenue Growth by Quarter and Year
Amneal Pharmaceuticals Inc 's Revenue results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
AMRX Revenue (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
IV Quarter |
December |
617.83
|
603.95
|
514.89
|
486.93
|
III Quarter |
September |
619.53
|
544.23
|
527.91
|
463.90
|
II Quarter |
June |
599.02
|
553.52
|
535.08
|
497.08
|
I Quarter |
March |
557.19
|
497.57
|
493.11
|
383.61
|
FY |
|
2,393.57
|
2,199.27
|
2,070.99
|
1,831.52
|
AMRX Revenue fourth quarter 2023 Y/Y Growth Comment |
Amneal Pharmaceuticals Inc reported Revenue growth of 2.3% year on year in the fourth quarter 2023, to $ 617.83 millions, this is lower than Amneal Pharmaceuticals Inc 's recent average Revenue growth of 7.18%.
Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue growth. While Amneal Pharmaceuticals Inc ' s Revenue increase of 2.3% ranks overall at the positon no. 1162 in the fourth quarter 2023.
|
AMRX Revenue ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
2.3 % |
17.3 % |
5.74 % |
51.15 % |
III Quarter |
September |
13.84 % |
3.09 % |
13.8 % |
15.5 % |
II Quarter |
June |
8.22 % |
3.45 % |
7.64 % |
26.54 % |
I Quarter |
March |
11.98 % |
0.9 % |
28.54 % |
-50.36 % |
FY |
|
8.83 % |
6.19 % |
13.07 % |
-3.06 % |
AMRX Revenue (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
IV Quarter |
December |
-0.27 % |
10.97 % |
-2.47 % |
4.96 % |
III Quarter |
September |
3.42 % |
-1.68 % |
-1.34 % |
-6.67 % |
II Quarter |
June |
7.51 % |
11.24 % |
8.51 % |
29.58 % |
I Quarter |
March |
-7.74 % |
-3.36 % |
1.27 % |
19.08 % |
FY (Year on Year) |
|
8.83 % |
6.19 % |
13.07 % |
-3.06 % |
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
29.38 % |
7.18 % |
-21.95 % |
(Mar 31 2021) |
|
(Mar 31 2020) |
|
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
29.38 % |
7.18 % |
-21.95 % |
(Mar 31 2021) |
|
(Mar 31 2020) |
|
Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Amneal Pharmaceuticals Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
62.17 % |
4.12 % |
-49.16 % |
(Dec 31 2018) |
|
|
AMRX's IV. Quarter Q/Q Revenue Comment |
In the IV. Quarter 2023 Amneal Pharmaceuticals Inc reported decrease in Revenue sequentially by -0.27% to $ 617.83 millions, from $ 619.53 millions released a quarter before.
Even cyclical influence which commonly elevate IV. Quarter 2023 Revenue, this clearly has not been substantial to salvage Amneal Pharmaceuticals Inc 's IV. Quarter 2023 performance, Sierra Thompson, a business observer allocated in Boston pointed out.
Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Amneal Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1322. |
|
|
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
62.17 % |
4.12 % |
-49.16 % |
(Dec 31 2018) |
|
|
AMRX's IV. Quarter Q/Q Revenue Comment |
In the IV. Quarter 2023 Amneal Pharmaceuticals Inc disclosed decrease in Revenue from the previous quarter by -0.27% to $ 617.83 millions, from $ 619.53 millions released in the previous reporting period.
Some cyclical circumstance could not recover the IV. Quarter for the Amneal Pharmaceuticals Inc , Sierra Thompson, a business observer allocated in Boston wrote, she voiced some pessimism conserning AMRX's outlook, she detected new challenges down the road for Amneal Pharmaceuticals Inc .
Within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Amneal Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1322. |
|
Amneal Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending (Dec 31 2023) |
12 Months Ending (Sep 30 2023) |
12 Months Ending (Jun 30 2023) |
12 Months Ending (Mar 31 2023) |
12 Months Ending (Dec 31 2022) |
Cumulative Revenue 12 Months Ending |
$ 2,393.57 |
$ 2,379.69 |
$ 2,304.39 |
$ 2,258.88 |
$ 2,199.27 |
Y / Y Revenue Growth (TTM) |
8.83 % |
12.77 % |
10.05 % |
8.84 % |
6.19 % |
Year on Year Revenue Growth Overall
Ranking |
# 1054 |
# 1712 |
# 2488 |
# 1042 |
# 0 |
Seqeuential Revenue Change (TTM) |
0.58 % |
3.27 % |
2.01 % |
2.71 % |
4.22 % |
Seq. Revenue Growth (TTM) Overall
Ranking |
# 1201 |
# 2143 |
# 2823 |
# 1782 |
# 0 |
Cumulative Revenue growth
Comment |
Assuming the Amneal Pharmaceuticals Inc 's fiscal year would have ended in Dec 31 2023, Amneal Pharmaceuticals Inc would have reprted above average annual Revenue improvement of 8.83% year on year, of $ 2,394 millions. This marks a slow-down of the companys growth trends and from the 12.77% rise in Sep 30 2023.
In the Healthcare sector 168 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1054, from total ranking in previous quarter at 1712. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
29.38 % |
7.18 % |
-21.95 % |
|
|
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
29.38 % |
7.18 % |
-21.95 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 67 |
Sector |
# 190 |
S&P 500 |
# 1201 |
|
Cumulative Revenue growth
Comment |
Assuming the Amneal Pharmaceuticals Inc 's fiscal year would have ended in Dec 31 2023, Amneal Pharmaceuticals Inc would have reprted above average annual Revenue improvement of 8.83% year on year, of $ 2,394 millions. This marks a slow-down of the companys growth trends and from the 12.77% rise in Sep 30 2023.
In the Healthcare sector 168 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1054, from total ranking in previous quarter at 1712. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
29.38 % |
7.18 % |
-21.95 % |
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
29.38 % |
7.18 % |
-21.95 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 67 |
Sector |
# 190 |
S&P 500 |
# 1201 |
|